GIMBHI’s daily mental health update — 9/16/26

💊 Lilly completes AtaiBeckley acquisition to advance neuroplastogens for treatment-resistant depression (Eli Lilly and Company, PR Newswire) — 09/11/26
TL;DR: Lilly closed its acquisition of clinical-stage AtaiBeckley to advance rapid-acting neuroplastogens including lead program BPL-003 for treatment-resistant depression.

🇨🇦 Montréal-based Onix raises $5M USD for AI library of health and wellness “experts” (Madison McLauchlan, BetaKit) — 09/09/26
TL;DR: Onix raised $5M USD led by AlphaEdison for a privacy-first app offering AI versions of wellness practitioners, using small models run locally with no chat logs kept and a 70/30 revenue share with experts.

🧬 CONNECTA Therapeutics raises €3.1M to advance Phase IIa trial of CTH120 for Fragile X syndrome (CONNECTA Therapeutics, GlobeNewswire) — 09/10/26
TL;DR: Barcelona-based CONNECTA closed €3.1M led by Clave Capital to fund its Phase IIa trial of neuroplasticity modulator CTH120 in 30 adult males with Fragile X syndrome, with topline data expected mid-2027.

💰 Vheda Health secures $47M from Agora — its first institutional capital in 13 years (Vheda Health, Newswire) — 09/10/26
TL;DR: Columbia, MD-based Vheda Health took its first outside capital — $47M from Agora — to scale its outcomes and analytics platform for health plans’ hardest-to-reach members, having already generated $975M+ in savings.